Welcome to SN Connect, the new gold standard for HCP-focused media.
For HR+/HER2- Early-Stage Breast Cancer at Increased Risk of Recurrence, Kisqali Has Benefits: Study
A Powerful Tool: Integrating Venetoclax into CLL Management Improves Survival
Oncologists Weigh in on Optimal Use of CDK 4/6 Inhibitors as Adjuvant Therapy in Early Breast Cancer
Imfinzi Improves Overall & Progression-Free Survival for Patients With Limited-Stage Small Cell Lung Cancer
Balversa's FDA Approval Means a New, Practice-Changing Option for FGFR-Positive Bladder Cancer
Unprecedented Progression-Free Survival for ALK-Positive Non-Small Cell Lung Cancer Using Lorbrena — What the New Research Means for Patients
Physicians Advised to Consider Rybrevant for EGFR Mutation-Positive NSCLC, Following FDA Approval
For Women With Heavily-Treated Triple-Negative or HR+, HER2- Metastatic Breast Cancer, Enfortumab Vedotin (Padcev) Shows Some Anti-Tumor Activity
Understanding Pluvicto (Lutetium-177) and PSMA PET Scans in Prostate Cancer Treatment
Elahere for Ovarian Cancer: Prevention, Detection & Management of Ocular Adverse Events